Info

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transporter mechanisms. The Company focuses its development and commercialization efforts on treatments of central nervous system (CNS), disorders. Its product candidate, XP13512, is being evaluated for the treatment of restless legs syndrome (RLS), in a Phase III clinical program in the United States and has also completed a Phase IIa clinical trial for the management of post-herpetic neuralgia (PHN), in the United States.(Source: 10-K)